PGXL is just days from moving into its much larger lab and office.
Along with more space, we’re also adding capabilities. Our techs have been out to California for training and are now up-to-speed on the AutoGenomics Infiniti. The first new assay being validated on the Infiniti is BRAF for colorectal cancer. We’re also migrating some of our exiting tests over to the new platform, which gives us greater flexibility in what we can offer our clients.
The new devices are part of partnership with AutoGenomics that you can read about atYahoo! Finance.